Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioAlliance Pharma Expands and Strengthens Its Industrial Property Assets

Published: Friday, July 12, 2013
Last Updated: Friday, July 12, 2013
Bookmark and Share
BioAlliance Pharma SA was granted two patents by the American and Japanese Offices protecting two of its products; Oravig® (miconazole) and Sitavig® (acyclovir).

With these two new patents, BioAlliance Pharma’s patent portfolio consists of 19 families of published patents, including 285 patents and patent applications for technologies or innovative products. More than 70 % of the portfolio is composed of patents providing long-term protection for the products.

“The industrial property is a key asset for BioAlliance and lies at the core of the Company’s growth strategy. The reinforcement and the territory expansion of our patents allow to ensure the largest and longest possible protection, optimizing our programs’ value. One such example is the grant of these two new patents”, declared Judith Greciet, CEO of BioAlliance Pharma.

New protection of Sitavig® in Japan

In addition to the first Japanese patent protecting the mucoadhesive tablet, and further to the patent protections obtained for Europe, the US and China, this grant is the first one specific to Sitavig® in Japan for the treatment of labial herpes.

New protection of Oravig® in the US

The American patent office announced its decision to deliver a new grant covering Oravig®, a miconazole mucoadhesive tablet for the treatment of oropharyngeal candidiasis. This new patent enables BioAlliance to expand the scope of protection already given by two US patents protecting Oravig® until 2022.

“These two patent grants strengthen and extend the protection for both Oravig® and Sitavig® in the US and Japan respectively while stressing out the innovative nature of the Lauriad® mucoadhesive tablet formulation. Oravig®’s patent reinforces and ensures its protection for about ten more years on the US territory while coinciding with the commercial product launch initiated by Vestiq”, stated Aude Michel, Head of Corporate Business Development of BioAlliance Pharma. “The protection obtained for Sitavig® until 2027 on the Japanese territory should reinforce its attractiveness in our search for commercial partners on an international level”.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioAlliance Pharma Announces Shareholders’ Meeting and Appointment of Independant Board Members
As a result of the shareholder’s meeting, Dr Russell Greig and Danièle Guyot-Caparros have been appointed as independent Board Members.
Monday, July 01, 2013
BioAlliance Pharma to Continue its Phase III Clinical Trial with Livatag®
The Data and Safety Monitoring Board (DSMB) has again recommended continuing the ReLive Phase III trial without modification.
Tuesday, May 14, 2013
BioAlliance Pharma’s Sitavig® Receives Market Authorization in the US
Authorization from the U.S. FDA for Sitavig® in the treatment of recurring Herpes labialis, marking the successful conclusion to the assessment procedure carried out by the American authorities.
Tuesday, April 16, 2013
BioAlliance Announces Phase I Trial for Fentanyl Lauriad® and the Submission of a Clonidine Lauriad® Phase II Clinical Trial Application
This clinical trial will evaluate the plasma pharmacokinetic parameters of Fentanyl Lauriad® in healthy volunteers.
Tuesday, October 13, 2009
BioAlliance Announces Positive Preliminary Pivotal Phase III Results in Herpes Labialis with Acyclovir Lauriad®
Study compared the efficacy and safety of a single dose acyclovir Lauriad® 50mg MBT versus matching placebo in recurrent oro-facial herpes.
Thursday, August 27, 2009
BioAlliance Pharma Submits Clinical Trial New Drug Application
Company announces submission of a Fentanyl Lauriad® clinical trial application to the French Drug Agency and approval by the Ethics Committee.
Wednesday, July 29, 2009
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!